Beech Tree Labs offers an attractive profile for investors and partners. Highlights include:
Novel Technology
-
Typically comprised of naturally-occurring molecules;
-
Physiologic dosage;
-
Large portfolio of domestic and foreign patents and patent applications.
Emerging Platform
-
Many unrelated diseases treated with different formulations by various investigators;
-
Elan Corporation, plc, licensed more than 30 patents to move forward their Alzheimer’s research now in FDA Phase 2 trials;
-
2 open IND applications on file;
-
Several publications in peer-reviewed journals;
-
Decades of pre-clinical and clinical studies;
-
Consistently positive results with placebo-level adverse effects.
The Company
-
An established base of patented product candidates, several ready for formal clinical evaluation;
-
A low burn rate and a proven cost and time effective product development strategy;
-
Products with inherently low risk of side effects and high profit margin potential;
-
No capital-intensive manufacturing process;
-
Robust pipeline.
Management Team Successes
-
13 FDA-authorized clinical trials;
-
2 IRB-approved clinical trials;
-
1 USDA-approved clinical trial;
-
World’s first live-virus fish vaccine;
-
Alzheimer’s disease pioneer;
-
Nutraceutical product, Mucolyxir® on the market;
-
Built extensive network of physicians, veterinarians, and medical scientists.
Security
- All patents owned, or licensed to, the company.
Markets
-
Pharmaceutical;
-
Nutraceutical;
-
Product candidates may also be developed in parallel for the above markets.